<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-8UN7DML4</identifier><date>2005</date><creator>Byrne Habič, Barbara</creator><creator>Mravljak, Janez</creator><creator>Pečar, Slavko</creator><relation>documents/znanstveni_clanki/farmacevtski_vestnik/html/urn_nbn_si_doc-8un7dml4.html</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/pdf/urn_nbn_si_doc-8un7dml4.pdf</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/txt/urn_nbn_si_doc-8un7dml4.txt</relation><format format_type="issue">2</format><format format_type="main">4 strani</format><format format_type="volume">56</format><format format_type="type">article</format><format format_type="extent">str. 120-123</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">1799793</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-8UN7DML4</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">dušikov oksid</subject><subject language_type_id="slv">inhibitorji</subject><subject language_type_id="slv">L-arginin</subject><subject language_type_id="slv">sintaze</subject><title>Dušikov oksid III: zaviralci prekomernega nastajanja</title></Record>